WO1995009658A1 - Alginate wound dressings - Google Patents

Alginate wound dressings Download PDF

Info

Publication number
WO1995009658A1
WO1995009658A1 PCT/GB1994/002024 GB9402024W WO9509658A1 WO 1995009658 A1 WO1995009658 A1 WO 1995009658A1 GB 9402024 W GB9402024 W GB 9402024W WO 9509658 A1 WO9509658 A1 WO 9509658A1
Authority
WO
WIPO (PCT)
Prior art keywords
alginate
molecular weight
dressing
dressings
wound
Prior art date
Application number
PCT/GB1994/002024
Other languages
French (fr)
Inventor
David Kershaw
Peter Michael John Mahoney
Original Assignee
E.R. Squibb And Sons, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E.R. Squibb And Sons, Inc. filed Critical E.R. Squibb And Sons, Inc.
Priority to DE69413048T priority Critical patent/DE69413048T2/en
Priority to BR9407669A priority patent/BR9407669A/en
Priority to AU76218/94A priority patent/AU677863B2/en
Priority to EP94926341A priority patent/EP0721355B1/en
Priority to JP7510660A priority patent/JPH09503142A/en
Priority to US08/619,740 priority patent/US5986164A/en
Priority to DK94926341T priority patent/DK0721355T3/en
Publication of WO1995009658A1 publication Critical patent/WO1995009658A1/en
Priority to FI961441A priority patent/FI115384B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28Polysaccharides or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)

Abstract

A wound dressing which comprises alginate characterised in that the alginate has a mannuronate content of 50 % to 80 %, has a molecular weight of 7000 to 40000 and has a monovalent : polyvalent ion content of from 10 to 30 : 70 to 90.

Description

ALGINATE WOUND DRESSINGS
The present invention relates to wound dressings, components thereof and to the methods of their manufacture. More specifically this invention relates to dressings suitable for use on exuding wounds, to alginate fibres for use therein and to the methods of their manufacture.
Exuding wounds such as ulcers, pressure sores and burns tend to produce copious volumes of exudate through at least part of the healing process. Many methods of coping with highly exuding wounds have been suggested, for example covering the wound with a highly permeable adhesive film, covering the wound with an adhesive hydrocolloid dressing or employing a dressing comprising an alginate. The use of an alginate wound dressing has proved to have many advantages, for example in terms of aiding healing of the wound as avoidance of damaging friable tissue on removal. Such dressings are described in: PCT/GB89/00706, EP 89917135.6, EP 89910126.5, EP 9120236.4 and PCT/GB92/00792.
Although known alginate dressings have good solubilities, there can be difficulties in removing them from wounds, for example in use they can partially dissolve to a weak gel which has to be washed from the wound. A more soluble dressing would be desirable to ease the removal by washing. Such a dressing has now been discovered.
In addition, it is known that alginate dressings have considerable disadvantages in that they, in common with other forms of dressing, do not sufficiently prevent tissues surrounding highly exuding wounds from becoming macerated. Maceration is not desirable because it can lead to increased friability of tissue. There is therefore a desire to provide a flat alginate dressing which is less likely to allow maceration of tissue surrounding highly exuding wounds. Such a flat dressing has now been discovered.
The present invention provides a wound dressing which comprises alginate characterised in that the alginate has a mannuronate content of 50% to 80%, has a molecular weight of 7000 to 40000 and has a monovalent : polyvalent ion content of from 10 to 30 : 70 to 90.
It has been found that dressings of the invention and the fibres of which they are composed hydrate rapidly. This greatly helps removal of the dressings and, in the case of flat dressings, significantly reduces the amount of lateral transport of fluid by capilarity. This in turn reduces the amount of exudate transported to the tissue surrounding the exuding wound so that the tendency for that tissue to become macerated is reduced or eliminated.
Alginates are produced by a variety of micro-organisms and marine algae which are the normal commercial source. The alginates being natural materials show considerable variety but are characterised in being block copolymers, the individual monosaccheride units being arranged into groups as blocks of mannuronic (M) and guluronic (G) residues. In addition to the repeating blocks each polymer chain can contain a proportion of alternating M and G monosaccharide units. It has been found that alginates containing 50% to 80% mannuronate can (if having an appropriate molecular weight and ionic content) be of particular use in wound dressings.
Alginates containing 50% to 85% of mannuronate can be obtained from species such as Ascophyllum nodosum,
Durvillea Protatonum, Lasonia Nigrescens and Ecklonia Maxima. Blends may be used if desired. Favoured alginates for use in the dressings of this invention will contain from 60% to 80% and preferably from 70% to 75% of mannuronate. A suitable source of such materials is Kelco, Tadworth, Surrey, UK. Suitable grades include manacol of the appropriate molecular weight range.
It has been found that the desirable properties of the dressings are best achieved if the molecular weight of the alginate is from 5000 to 80000, aptly from 7000 to 40000, more suitably from 12000 to 35000 and preferably from 15000 to 30000, for example about 20000 to 25000. A fairly broad distribution of molecular weights within the alginate polymer population is acceptable. The molecular weight referred to is the number average molecular weight. One suitable method of determining the number average molecular weight is given in the descriptions hereinafter. (Thus the molecular weight is aptly at least 5000, more aptly at least 7000, yet more aptly at least 15000 and favourably, is at least 20000 aptly less than 80000, more aptly less than 40000, yet more aptly less than 35000 and more suitably less than 30000.
It has also been found that the desirable properties of the dressings are best achieved if the ratio between polyvalent ions (normally divalent ions) such as calcium and monovalent ions such as sodium is from 70 - 90 : 30 - 10, more suitably from 75 - 85 : 25 - 15 and preferably 80:20. Obviously small amounts of other ions may be present as long as they are pharmaceutically acceptable and do not interfere with the properties of the dressing.
A particularly suitable dressing of this invention will comprise alginate characterised in that the alginate has a mannuronate content of 60% to 80%, a molecular weight of 15000 to 25000 and a ratio of sodium ion to calcium ions of 15 to 25 : 75 to 85.
A preferred dressing of this invention will comprise alginate characterised in that the alginate has a mannuronate content of 70% to 75%, a molecular weight of about 20000 and a ratio of calcium ion to sodium ion 80:20.
The alginate is normally and preferably present as fibres. The fibres may be long or short, tangled or untangled, knitted or woven as desired. The dressing may be in the form of a flat needled or non-needled wound dressing, a sliver product (which is particularly suitable for cavities) , a roving product (which is especially suitable for use in sinus cavities) , an island dressing, as a yarn or knitted or woven fabric. The previously described patent applications (which are incorporated herein by reference) may be inspected for suitable dressing formats and manufacturing methods etc.
A wound dressing according to the present invention may further be provided with a moisture vapour permeable film, for example a polyurethane, polyetherester derivatives, a polyether amide and the like. Generally the polymers will be hydrophilic. Aptly such films will be from 15 to 50 microns thick, more usually 20 to 30 microns, for example 25 microns. The film layer may be applied directly to the surface of an alginate pad but more suitably will be adhered by means of an adhesive. Such adhesives are preferably moisture vapour permeable, for example an acrylic, polyurethane or polyether adhesive of which acrylic adhesives are preferred.
Dressings of this invention are normally provided sterile contained within a bacteria proof pouch.
A particularly suitable dressing of this invention comprises a pad of alginate fibres. These pads can be referred to as a "flat" dressing because they are generally produced flat but of course they can be flexible and adapt to the shape of a wound. In general these are provided as pads of from 4 x 4 x 0.1cm up to 20 x 20 x 0.3cm although other shapes and sizes are common. Dressings of this type are generally laid over exuding wounds such as ulcers or burns. The dressings of this invention do not need to be cut to shape to avoid maceration when used in this manner. They are particularly easy to remove because even if the wound covering portion gels or dissolves, the integrity of the wound surrounding portion is maintained and so allows the dressing to be lifted off. If any residual material is left in the wound it is particularly easy to remove by irrigation because of the high solubility of the fibres.
When used to cover exuding wounds and even when over- wrapped with four layers of compression bandage, dressings of this invention were found not to cause maceration of surrounding skin and to be easily removed. The dressings of this invention may be made in conventional manner, for example as described in the previously mentioned patents. They may contain antioxidants or preservatives if desired. The dressings may be sterilized by radiation if desired.
Description 1
A suitable method of molecular weight determination of alginate wound dressings.
Alginate solutions were prepared from wound dressing samples by titration with a concentrated aqueous Calgon solution (that is sodium hexametaphosphate, for example at 10% w/w) . The Calgon solution was added dropwise to the wound dressing fibres, which were agitated with a magnetic stirring bar until the fibres had dissolved and a non-turbid. solution was obtained. The concentrated (approximately 0.7%) alginate solutions were diluted with aqueous sodium nitrate to yield solutions containing approximately 0.2% alginate and 0.1M NaNOβ. The dilute alginate solutions were filtered through a 0.45 micron filter prior to injection into the Size Exclusion chromatography/Multiple Angle Laser Light Scattering instrument (SEC/MALLS) .
Molecular weight distributions were determined by SEC/MALLS. Our suitable system comprises a Hewlett- Packard Liquid Chromatograph Model 1084B, a 30cm Ultrahydrogel Linear column (Waters) with a guard column, a DAWN Model F Light Scattering Detector and a Waters 410 Differential Refractometer. The sample is injected into the eluant flow (aqueous 0.1M NaNθ3 with 0.01% NaN3 as an antimicrobial agent) and is separated based on molecular - 1 -
size by the size exclusion chromatography column. As the sample elutes from the column the molecular weight and concentration profiles are determined by the light scattering and refractive index detectors, respectively. An index of refraction increment (dn/dc) of 0.145 was used to determine the sample concentration (and molecular weight) as a function of elution volume. This value was obtained from the literature (Paoletti et al (1991) Carbohydrate Polymers, 15, 171; Mackie et al (1980) Biopolymers J 19, 1839; Strand et al (1982)
Macromolecules, 15, 570) and is typical for alginates in aqueous salt solutions. The light scattering detector was calibrated with a series of pullulan standards (Mw = 200,000; 400,000 and 800,000 g/mole) and a previously measured (by Paoletti) alginate sample of Mw = 210,000.
Weight average and number-average molecular weights, as well as polydispersity indices (Mw/Mn) , were determined for each sample. The molecular weight results for the algin samples are given in the table below.
Sample Mn*(g/mole) Mw(g/mole) Mw/Mn
Example 1 21,000 92,000 4.4
SORBSAN 120,000 300,000 2.5
The SORBSAN wound dressing has much higher and significantly different molecular weight distribution than the sample of Example 1 (Mw = 300,000 vs. 92,000 g/mole) . Example 1 had a broader molecular weight distribution than that of SORBSAN.
Example 1
Manufacture of low molecular weight, high mannuronate.
80:20 alginate fabric (a) Low molecular weight, high mannuronate calcium alginate fibre
The fibre was prepared by the method of preparation 1 of PCT/GB89/01009 employing sodium alginate powder wherein the alginate had a number average weight molecular weight of 21,000 and had a mannuronate content of 70%.
(b) Low molecular weight, high mannuronate. 80:20 alginate fabric manufacture of
The fabric was prepared by the method of preparation 2 of PCT/GB89/01009 but employing low molecular weight, high mannuronate calcium alginate fibre as prepared in part (a) .
Examples 2-5
Alternative manufacture of low molecular weight, high mannuronate. 80:20 alginate fabric.
The fabrics were prepared by the methods of preparations 3 to 6 of PCT/GB98/01009 adapted by the use of calcium alginate as prepared in Example 1(a) herein.
Example 6
A fabric as prepared in Example 1 was cut to 5cm x 5cm square and placed in the centre of a water vapour permeable polyurethane film of 8cm x 8cm square and 21 microns thick. The face of the film on which the fabric was placed was provided with a pressure sensitive adhesive layer comprising an acrylic adhesive. A silicone release paper was then placed on the remote face of the film and the paper was trimmed to size.

Claims

Claims
1. A wound dressing which comprises alginate characterised in that the alginate has a mannuronate content of 50% to 80%, has a molecular weight of 7000 to 40000 and has a monovalent : polyvalent ion content of from 10 to 30 : 70 to 90.
2. A dressing according to claim 1, which has a mannuronate content of 60 to 80%.
3. A dressing according to claim 2, which has a mannuronate content of 70 to 75%.
4. A dressing according to any of claims 1 to 3, wherein the alginate has a molecular weight of 12000 to 35000.
5. A dressing according to claim 4, wherein the alginate has a molecular weight of 15000 to 30000.
6. A dressing according to claims 1 to 5, which has a monovalent:polyvalent ion content of 15 to 25 : 75 to 85.
7. A dressing according to any of claims 1 to 6, wherein the monovalent ion is sodium and the polyvalent ion is calcium.
8. A wound dressing which comprises alginate characterised in that the alginate has a mannuronate content of 60% to 80%, a molecular weight of 15000 to 25000 and a ratio of sodium ion to calcium ion of 15 to 25 : 75 to 85.
9. A wound dressing which comprises alginate characterised in that the alginate has a mannuronate content of 70% to 75%, a molecular weight of about 20000 and a ratio of calcium ion to sodium ion 80:20.
10. A dressing according to any of claims 1 to 9, which further comprises a moisture vapour permeable film.
PCT/GB1994/002024 1993-10-01 1994-09-16 Alginate wound dressings WO1995009658A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE69413048T DE69413048T2 (en) 1993-10-01 1994-09-16 ALGINATE Wound Bandages
BR9407669A BR9407669A (en) 1993-10-01 1994-09-16 Wound bandage comprising alginate
AU76218/94A AU677863B2 (en) 1993-10-01 1994-09-16 Alginate wound dressings
EP94926341A EP0721355B1 (en) 1993-10-01 1994-09-16 Alginate wound dressings
JP7510660A JPH09503142A (en) 1993-10-01 1994-09-16 Alginate wound dressing
US08/619,740 US5986164A (en) 1993-10-01 1994-09-16 Alginate wound dressings
DK94926341T DK0721355T3 (en) 1993-10-01 1994-09-16 alginate wound dressings
FI961441A FI115384B (en) 1993-10-01 1996-03-29 Alginaattihaavasiteitä

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939320232A GB9320232D0 (en) 1993-10-01 1993-10-01 Alginate wound dressing
GB9320232.3 1993-10-01

Publications (1)

Publication Number Publication Date
WO1995009658A1 true WO1995009658A1 (en) 1995-04-13

Family

ID=10742812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1994/002024 WO1995009658A1 (en) 1993-10-01 1994-09-16 Alginate wound dressings

Country Status (16)

Country Link
US (1) US5986164A (en)
EP (1) EP0721355B1 (en)
JP (1) JPH09503142A (en)
AT (1) ATE170403T1 (en)
AU (1) AU677863B2 (en)
BR (1) BR9407669A (en)
CA (1) CA2173238A1 (en)
CZ (1) CZ286338B6 (en)
DE (1) DE69413048T2 (en)
DK (1) DK0721355T3 (en)
ES (1) ES2122322T3 (en)
FI (1) FI115384B (en)
GB (1) GB9320232D0 (en)
NZ (1) NZ273062A (en)
TW (1) TW321598B (en)
WO (1) WO1995009658A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002283A1 (en) * 1994-07-15 1996-02-01 E.R. Squibb & Sons Inc. Alginate fibres, method of preparation and use
IT201900022803A1 (en) * 2019-12-03 2021-06-03 Univ Degli Studi Di Ferrara ALGINATE GEL FOR THE MEDICATION OF SKIN WOUNDS

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3750495A (en) * 1994-10-28 1996-05-23 Innovative Technologies Limited Dehydrated hydrogels
US6281341B1 (en) 1997-04-30 2001-08-28 Biomm, Inc. & University Of Miami Hetero-polysaccharide conjugate and methods of making and using the same
US6174544B1 (en) 1999-09-16 2001-01-16 Euromed, Inc. Easy-release alginate wound healing device and method
US6685978B1 (en) 2000-04-04 2004-02-03 Cp Kelco Aps Gelled and gellable compositions for food products
US6663596B2 (en) 2001-08-13 2003-12-16 Scimed Life Systems, Inc. Delivering material to a patient
WO2007120616A2 (en) * 2006-04-11 2007-10-25 Tyco Healthcare Group Lp Wound dressings with anti-microbial and zinc-containing agents
BRPI0714386A2 (en) * 2006-07-14 2012-12-25 Fmc Biopolymer As hydrogel, bead, methods for producing a hydrogel or bead, for implanting an implantable medical bead or device and cells in a patient, for blocking blood vessels, and for forming a hydrogel, implantable medical device, drug release formulation, contrast or radioopaque material, and, embolic therapeutic composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012471A1 (en) * 1988-06-24 1989-12-28 Britcair Limited Wound dressing
WO1990001954A1 (en) * 1988-08-31 1990-03-08 Britcair Limited Wound dressing
WO1991011205A1 (en) * 1990-01-23 1991-08-08 Trancel Corporation Mannuronic acid containing alginate wound healing composition and method
EP0476756A1 (en) * 1990-09-17 1992-03-25 Cv Laboratories Limited Improved absorbency alginate fabric and a method for its preparation
WO1992019802A1 (en) * 1991-05-01 1992-11-12 C.V. Laboratories Limited Alginate fabric, its use in wound dressings and surgical haemostats and a process for its manufacture
WO1993016111A1 (en) * 1992-02-12 1993-08-19 Ulrich Zimmermann Mitogen-free substance, its preparation and its use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238685A (en) * 1988-08-31 1993-08-24 Britcair Limited Wound dressing
FI532U1 (en) * 1992-11-04 1993-02-17 Valmet Paper Machinery Inc Vaetskeavskiljningsventil Foer sprutroeret av en pappers- eller kartonmaskin
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012471A1 (en) * 1988-06-24 1989-12-28 Britcair Limited Wound dressing
WO1990001954A1 (en) * 1988-08-31 1990-03-08 Britcair Limited Wound dressing
WO1991011205A1 (en) * 1990-01-23 1991-08-08 Trancel Corporation Mannuronic acid containing alginate wound healing composition and method
EP0476756A1 (en) * 1990-09-17 1992-03-25 Cv Laboratories Limited Improved absorbency alginate fabric and a method for its preparation
WO1992019802A1 (en) * 1991-05-01 1992-11-12 C.V. Laboratories Limited Alginate fabric, its use in wound dressings and surgical haemostats and a process for its manufacture
WO1993016111A1 (en) * 1992-02-12 1993-08-19 Ulrich Zimmermann Mitogen-free substance, its preparation and its use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002283A1 (en) * 1994-07-15 1996-02-01 E.R. Squibb & Sons Inc. Alginate fibres, method of preparation and use
IT201900022803A1 (en) * 2019-12-03 2021-06-03 Univ Degli Studi Di Ferrara ALGINATE GEL FOR THE MEDICATION OF SKIN WOUNDS

Also Published As

Publication number Publication date
NZ273062A (en) 1996-10-28
EP0721355B1 (en) 1998-09-02
DE69413048D1 (en) 1998-10-08
CZ286338B6 (en) 2000-03-15
FI961441A0 (en) 1996-03-29
DK0721355T3 (en) 1999-06-07
ATE170403T1 (en) 1998-09-15
TW321598B (en) 1997-12-01
BR9407669A (en) 1997-01-28
EP0721355A1 (en) 1996-07-17
AU677863B2 (en) 1997-05-08
DE69413048T2 (en) 1999-01-21
ES2122322T3 (en) 1998-12-16
CA2173238A1 (en) 1995-04-13
CZ91696A3 (en) 1996-08-14
FI115384B (en) 2005-04-29
FI961441A (en) 1996-03-29
JPH09503142A (en) 1997-03-31
AU7621894A (en) 1995-05-01
US5986164A (en) 1999-11-16
GB9320232D0 (en) 1993-11-17

Similar Documents

Publication Publication Date Title
Zhang et al. Alginate hydrogel dressings for advanced wound management
US6534083B2 (en) Hydrogels
Yusof et al. Flexible chitin films as potential wound‐dressing materials: Wound model studies
US4537767A (en) Method for cleansing fluid discharging skin surfaces, wounds and mucous membranes and means for carrying out the method
Singh et al. Synthesis and characterization of tragacanth gum based hydrogels by radiation method for use in wound dressing application
bt Ibrahim et al. Sodium alginate film: The effect of crosslinker on physical and mechanical properties
Nayak et al. Study of the keratin-based therapeutic dermal patches for the delivery of bioactive molecules for wound treatment
RU2422133C1 (en) Hydrophylic gel, method of its obtaining (versions), wound covering and based on it bandage means
US5986164A (en) Alginate wound dressings
US8821933B2 (en) Polymers and hydrogels
EP0927013B1 (en) Wound dressing
Panawes et al. Antimicrobial mangosteen extract infused alginate-coated gauze wound dressing
WO1996002284A1 (en) Alginate fibre, process for the preparation thereof and use
CN111053947A (en) Konjac glucomannan/fish gelatin hydrogel as well as preparation method and application thereof
Morgan Alginate dressings: part 1: historical aspects
O’Brien et al. Just a Flesh Wound? A Detailed Review of Modern Dressings
US5820874A (en) Alginate fibres, method of preparation and use
KR100315168B1 (en) Preparation of silk fibroin sponge membrane for wound covering materials
Turner Interactive dressings used in the management of human soft tissue injuries and their potential in veterinary practice
JPH08294527A (en) Wound coating material and its production
JPS6152872A (en) Wound covering protective tape
Bairagi et al. Alginate in Wound Care
Morgan Alginate dressings: part 2: product guide
Sanapala et al. Supramolecular hydrogels as drug delivery systems for nerve regeneration and wound healing
Yang et al. A pH responsive tannic acid/quaternized carboxymethyl chitosan/oxidized sodium alginate hydrogels for accelerated diabetic wound healing and real-time monitoring

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994926341

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 273062

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1996-916

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 961441

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 2173238

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 08619740

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994926341

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1996-916

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1994926341

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1996-916

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 961441

Country of ref document: FI